18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma
Metrics: PDF 931 views | HTML 1256 views | ?
Makoto Yamamoto1, Tetsuya Tsujikawa2, Shizuka Yamada1, Tetsuji Kurokawa2, Akiko Shinagawa2, Yoko Chino2, Tetsuya Mori2, Yasushi Kiyono2, Hidehiko Okazawa2, Yoshio Yoshida1
1Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
2Biomedical Imaging Research Center, University of Fukui, Fukui, Japan
Yoshio Yoshida, email: firstname.lastname@example.org
Keywords: 18F-FES PET, 18F-FDG PET, uterine sarcoma, prognostic prediction
Received: September 30, 2016 Accepted: January 29, 2017 Published: February 06, 2017
We investigated whether 16α-[18F]-fluoro-17β-estradiol (18F-FES) and 18F-fluoro-deoxyglucose (FDG) uptake measured using positron emission tomography (PET) predicted prognosis in 18 patients with different histological subtypes of uterine sarcoma. Standardized uptake values (SUVs) and 18F-FDG/18F-FES SUV ratios were determined, and their correlations with progression-free (PFS) and overall survival (OS) were examined. Ten patients died from local recurrence or metastasis, and one more experienced recurrence, during the at least 36-month follow-up period. Patients with higher 18F-FDG SUVs (> 5.5) had worse OS (p = 0.007) and tended toward worse PFS (p = 0.11), while patients with lower 18F-FES SUVs (≤ 1.5) had worse PFS (p = 0.03) and tended toward worse OS (p = 0.19). Patients with 18F-FDG/18F-FES ratios > 2.6 had worse PFS (p = 0.009) and OS (p = 0.005). The 5-year PFS and OS rates were 75% and 88% for patients with lower ratios, but were only 10% and 20% for those with higher ratios. These results suggest that pretreatment tumor 18F-FDG/18F-FES ratio is useful for predicting the prognosis of uterine sarcoma patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.